Current report filing

Note 19 - Segments - Segment Information (Details)

v3.8.0.1
Note 19 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Tc99m tilmanocept sales revenue $ 9,000 $ 18,000 $ 4,000 $ 9,000 $ 6,000 $ 9,000 $ 4,000 $ 39,601 $ 19,075 $ 13,200
Tc99m tilmanocept license revenue 1,296,000 246,000 254,000 250,000 550,000 250,000 83,000 1,795,625 1,133,333 300,000
Grant and other revenue 1,022,000 511,000 917,000 686,000 540,000 477,000 654,000 190,000 3,136,408 1,860,953 1,740,896
Revenues                 4,971,634 3,013,361 2,054,096
Cost of goods sold, excluding depreciation and amortization                 62,260 3,226  
Research and Development Expense                 7,138,080 10,562,729 15,116,978
Selling, general and administrative expenses, excluding depreciation and amortization [1]                 7,466,487 10,365,950  
Depreciation, Depletion and Amortization, Nonproduction [2]                 453,549 522,196  
Income (loss) from operations (3,240,000) (910,000) (2,241,000) (3,758,000) (3,463,000) (4,912,000) (3,443,000) (6,623,000) (10,148,742) [3] (18,440,740) [3] (22,591,492)
Other income (expense), excluding equity in the loss of R-NAV, LLC [4]                 2,786,007 (4,298,604)  
Equity in loss of R-NAV, LLC                 (15,159) (305,253) (523,809)
Net loss from continuing operations                 (7,377,894) (23,044,597)  
Loss from discontinued operations, net of tax effect (1,764,000) 1,702,000 (5,865,000) (1,004,000) (564,000) (1,562,000) (1,520,000) (1,309,000) (6,931,137) (4,518,938) [5] (5,367,801)
Net loss                 (14,309,031) (27,563,535) (35,726,669)
Total assets, net of depreciation and amortization 12,461,676       14,964,513       12,461,676 14,964,513  
Capital expenditures                 1,847 39,001 1,114,448
Net loss from continuing operations                 (7,377,894) (23,044,597)  
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax (1,764,000) $ 1,702,000 $ (5,865,000) $ (1,004,000) (564,000) $ (1,562,000) $ (1,520,000) $ (1,309,000) (6,931,137) (4,518,938) [5] $ (5,367,801)
UNITED STATES                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization 12,329,143       14,552,834       12,329,143 14,552,834  
Non-US [Member]                      
Tc99m tilmanocept sales revenue                 39,601 19,075  
Total assets, net of depreciation and amortization 132,533       411,679       132,533 411,679  
Diagnostics Segment [Member]                      
Tc99m tilmanocept license revenue                 1,795,625 1,133,333  
Grant and other revenue                 3,011,642 1,860,953  
Revenues                 4,846,868 3,013,361  
Cost of goods sold, excluding depreciation and amortization                 62,260 3,226  
Research and Development Expense                 6,375,929 9,831,834  
Selling, general and administrative expenses, excluding depreciation and amortization [1]                  
Depreciation, Depletion and Amortization, Nonproduction [2]                 56,317 232,091  
Income (loss) from operations [3]                 (1,647,638) (7,053,790)  
Other income (expense), excluding equity in the loss of R-NAV, LLC [4]                  
Equity in loss of R-NAV, LLC                  
Net loss from continuing operations                 (1,647,638) (7,053,790)  
Loss from discontinued operations, net of tax effect                 (6,931,137) (5,713,598) [5]  
Net loss                 (8,578,775) (12,767,388)  
Capital expenditures                 26,589  
Net loss from continuing operations                 (1,647,638) (7,053,790)  
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                 (6,931,137) (5,713,598) [5]  
Diagnostics Segment [Member] | UNITED STATES                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization 3,815,271       4,161,029       3,815,271 4,161,029  
Diagnostics Segment [Member] | Non-US [Member]                      
Tc99m tilmanocept sales revenue                 39,601 19,075  
Total assets, net of depreciation and amortization 131,752       410,666       131,752 410,666  
Therapeutics Segment [Member]                      
Tc99m tilmanocept license revenue                  
Grant and other revenue                 124,766  
Revenues                 124,766  
Cost of goods sold, excluding depreciation and amortization                  
Research and Development Expense                 762,151 730,895  
Selling, general and administrative expenses, excluding depreciation and amortization [1]                 63,158 123,884  
Depreciation, Depletion and Amortization, Nonproduction [2]                  
Income (loss) from operations [3]                 (700,543) (854,779)  
Other income (expense), excluding equity in the loss of R-NAV, LLC [4]                  
Equity in loss of R-NAV, LLC                  
Net loss from continuing operations                 (700,543) (854,779)  
Loss from discontinued operations, net of tax effect                 [5]  
Net loss                 (700,543) (854,779)  
Capital expenditures                  
Net loss from continuing operations                 (700,543) (854,779)  
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                 [5]  
Therapeutics Segment [Member] | UNITED STATES                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization 15,075             15,075  
Therapeutics Segment [Member] | Non-US [Member]                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization              
Corporate Segment [Member]                      
Tc99m tilmanocept license revenue                  
Grant and other revenue                  
Revenues                  
Cost of goods sold, excluding depreciation and amortization                  
Research and Development Expense                  
Selling, general and administrative expenses, excluding depreciation and amortization [1]                 7,403,329 10,242,066  
Depreciation, Depletion and Amortization, Nonproduction [2]                 397,232 290,105  
Income (loss) from operations [3]                 (7,800,561) (10,532,171)  
Other income (expense), excluding equity in the loss of R-NAV, LLC [4]                 2,786,007 (4,298,604)  
Equity in loss of R-NAV, LLC                 (15,159) (305,253)  
Net loss from continuing operations                 (5,029,713) (15,136,028)  
Loss from discontinued operations, net of tax effect                 1,194,660 [5]  
Net loss                 (5,029,713) (13,941,368)  
Capital expenditures                 1,847 12,412  
Net loss from continuing operations                 (5,029,713) (15,136,028)  
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax                 1,194,660 [5]  
Corporate Segment [Member] | UNITED STATES                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization 8,498,797       10,391,805       8,498,797 10,391,805  
Corporate Segment [Member] | Non-US [Member]                      
Tc99m tilmanocept sales revenue                  
Total assets, net of depreciation and amortization $ 781       $ 1,013       $ 781 $ 1,013  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
[2] Depreciation and amortization is reflected in research and development ($0 and $10,617 for the years ended December 31, 2016 and 2015, respectively), and selling, general and administrative expenses ($397,232 and $460,839 for the years ended December 31, 2016 and 2015, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4] Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.
[5] Amount not allocated to a reportable segment represents contingent consideration recognized related to 2015 GDS Business revenue royalties pursuant to the 2011 sale of the GDS Business to Devicor, net of tax effect. See Note 1(a).